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Abstract
During the last two decades, epidemiology has undergone a rapid evolution toward collaborative 
research. The proliferation of multi-institutional, interdisciplinary consortia has acquired particular 
prominence in cancer research. Herein, we describe the characteristics of a network of 49 
established cancer epidemiology consortia (CEC) currently supported by the Epidemiology and 
Genomics Research Program (EGRP) at the National Cancer Institute (NCI). This collection 
represents the largest disease-based research network for collaborative cancer research established 
in population sciences. We describe the funding trends, geographic distribution and areas of 
research focus. The CEC have been partially supported by 201 grants and yielded 3876 
publications between 1995 and 2011. We describe this output in terms of interdisciplinary 
collaboration and translational evolution. We discuss challenges and future opportunities in the 
establishment and conduct of large-scale team science within the framework of CEC, review 
future prospects for this approach to large scale, interdisciplinary cancer research and describe a 
model for the evolution of an integrated Network of Cancer Consortia optimally suited to address 
and support 21st century epidemiology.
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Introduction
The transition towards large scale collaborations has been a hallmark in many fields of 
research in the last few decades (1). In epidemiology, and especially in the genomic 
epidemiology of complex diseases, this trend has been supported by a convergence of 
factors, including the rapid development of increasingly sophisticated genomic technologies 
(2), the progressive building of large population resources such as cohorts and biobanks (3, 
4), and the requirement for larger sample sizes to address small effects. As a consequence, 
epidemiologic research on the genetic and environmental determinants of complex diseases 
has experienced a paradigm shift toward “Big and Bigger Science”, embodied by the rise of 
consortia as “hubs” of collaborative and interdisciplinary research within the framework of 
population sciences (5). Cancer epidemiology has been markedly affected by the advent of 
such collaborative infrastructures. Here, we examine the impact of research originating from 
interdisciplinary cancer consortia from 1995 to 2011, based on our experience with a 
network of 49 cancer-related consortia supported by the Epidemiology and Genomics 
Research Program (EGRP) of the National Cancer Institute (NCI). To our knowledge, this is 
the largest disease-based research network for collaborative, population-based research 
currently in existence. The reported analysis offers insights about the growth, impact, and 
future prospects of CECs as well as their role in supporting high-impact interdisciplinary 
research.
Definition
We define a consortium as “A group of scientists from multiple institutions who have agreed 
to cooperative research efforts involving, but not limited to, pooling of information from 
more than one study for the purpose of combined analyses and collaborative projects. Such 
consortia are geared to address scientific questions that cannot otherwise be addressed 
through the effort of a team of investigators at a single institution due to scope, resources, 
population size, or the need for an interdisciplinary approach” (6). The Cancer 
Epidemiology Consortia (CEC) network is a group of eligible cancer consortia which have 
received different forms of support by the National Cancer Institute (NCI) since 1995.
Consortia included in this network have either contacted the NCI/EGRP to be listed or have 
been specifically solicited through a targeted initiative. When applying to be listed on the 
EGRP website, each consortium is required to provide the following to be eligible: a 
description of cancer-related research questions that can be uniquely addressed by that 
consortium because of its characteristics (e.g. size and characteristics of population, enrolled 
biobank infrastructure, involvement of an interdisciplinary team of scientists from multiple 
institutions, etc.); an existing or proposed organizational structure and leadership plan; and a 
statement of commitment to data sharing within and outside the consortium. Since emerging 
consortia can experience a substantial lag time before beginning to publish in a substantive 
manner, we have limited the reported analyses to established cancer epidemiology consortia 
(CEC) that were launched before 2010. A complete list of the 49 established EGRP 
consortia included in the analyses, along with descriptive information on each appears in 
Table 1.
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Characteristics of the Cancer Epidemiology Consortia
A common characteristic of the 49 established CEC is that each team has not assembled 
uniquely to execute one project, but their collaborations extend through time and across 
research projects that vary in design and complexity. Only 3 of these CEC had assembled in 
response to solicitations by the NCI or other NIH institutes (7–9), with the remainder 
coalescing spontaneously to address diverse research agendas. Funding for consortia-related 
research is provided by EGRP/NCI through a variety of investigator-initiated mechanisms or 
through support for communication and research networking activities such as meetings or 
teleconferences. Most consortia (n=41, 84%) focus on a single cancer type. The remaining 8 
(16%) CEC study multiple cancers, specific translational topics (e.g. radiogenomics), or 
focus on diverse ethnic populations (Hispanics, African, Asian and Caribbean) in US and 
abroad (Table 1). Most CECs are international in nature, with the largest distribution of 
collaborating groups in high and mid-level income countries (Supplemental Figure 1). All 
49 CECs have some type of associated biorepository.
Websites for CEC and Consortium Policies
Public websites are an essential tool for communication and global sharing of study results, 
dissemination of research tools, and provide a conduit to data sharing and research 
opportunities for large collaborative groups. Forty (82%) CEC have developed publicly 
available websites (reviewed from March 4–14, 2013): thirty-four (85%) included 
information on CEC leadership and twenty (50%) detailed the CEC organizational structure. 
Eighteen (45%) of the CEC websites included information on consortium membership 
requirements, nine (23%) included submission guidelines for new project proposals, and 
seven (18%) had eligibility requirements and contact information for participant enrollment. 
Twenty-one (53%) of the CEC websites included a restricted access area (portal) reserved 
for consortia members communication and internal data sharing.
CEC websites (accessed May 13–16, 2013), associated grant applications, and descriptive 
manuscripts were reviewed to determine if CEC had established data sharing policies, as 
was intended. In cases where no policy was found the CEC liaison or lead investigator was 
contacted and asked if the CEC had a data sharing policy in place. Overall, 29 (59%) had 
data sharing policies, 3 (6.1%) were in the process of developing them, 10 (20.4%) did not 
have policies in place, and for 8 (16.3%) CEC we were unable to confirm whether or not 
they had data sharing policies. Consortia supported entirely or in part through NCI-awarded 
grants and cooperative agreements are mandated to comply with the NIH data and resource 
sharing policies for what concerns the specific aims listed on the funded grants or 
cooperative agreements (10).
Grants Funding for CEC
In order to evaluate the investment in terms of funding support and the scientific 
productivity of CEC, we reviewed all the EGRP grants that were related to the 49 
established CEC. Overall, 201 grants, funded by EGRP between fiscal year (FY) 1995 and 
2011, were identified as consortium related by searching the NCI Portfolio Management 
Application (PMA) database (v14.0.3). Grant coding is conducted by EGRP program staff 
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and consortium codes were confirmed through a manual review of the EGRP grant portfolio. 
A grant was defined as consortium- related if it directly supported the main research 
activities and/or infrastructure of the consortium, or if it explicitly relied on the consortium’s 
resources to conduct the proposed research project. An analysis of CEC-related grants shows 
a linear increase of investment in consortial research by EGRP from FY 1995–2011 
(Supplemental Figures 2A and 2B). The average yearly increase in total number and total 
direct cost for EGRP CEC associated grants was 5.3 and $4.2 million respectively; in 
contrast the total number of grants funded by EGRP has been flat since 1997 and the total 
direct cost of the whole portfolio has increased at a much slower rate (Supplemental Figures 
3A and 3B). Starting in 2002, funding for projects that are collaborations between CEC 
increased over time. This reflects the increasing number of CEC as well as increases in the 
size and complexity of the collaborative network. While the total costs of CEC associated 
grants has been increasing, the average cost per grant has been relatively flat since 1998 and 
the fraction of small grants (<$250K in direct costs per year) increased substantially from 
2002 to 2007. This trend towards smaller grants is not seen in the overall EGRP portfolio 
(Supplemental Figures 4A and 4B).
The success rate of CEC-related grants (percentage of reviewed applications that receive 
funding) was compared to the success rate of EGRP-funded and NIH-funded grants (all 
mechanisms). Data were extracted from NIH RePORTER (11) (accessed 5/6/2013) and the 
NCI Portfolio Management Application (PMA) database (v14.0.3, accessed 4/30/2013). The 
success rate of CEC-related grants (48%) was consistently higher than the success rates for 
EGRP grants (28%) and NIH grants (25%) since FY 2000 (Table 2). This may reflect many 
factors, including the ready availability of resources and infrastructure in established 
consortia, increased communication across participating scientists and groups (12) as well as 
a more intense pre-submittal review of grants applications by the multiple participating 
investigators.
Productivity and Impact
To measure CEC scientific productivity, 3,876 CEC-related manuscripts were identified 
using three different methods. First, the CEC websites (if available) were searched for 
listings of manuscripts (websites initially accessed the week February 20, 2012 and checked 
for updates on 1/21/2013). Second, the CEC names and abbreviations were used as search 
terms for PubMed (13) queries (search performed on April, 30 2012); the titles and abstracts 
of these manuscripts were reviewed and results returned due to ambiguity in the search 
terms (such as a different organization having the same abbreviation as the CEC) were 
excluded. Finally, the NCI code and serial numbers of the 201 consortium-related EGRP 
grants (as identified above) were used as search terms in PubMed (search performed on May 
13, 2012) to identify grant-related manuscripts. Results of these searches were combined 
and duplicate manuscripts and manuscripts published before the initiation year of the oldest, 
associated consortium and after 2011 were removed. The ascertainment and censoring, of 
EGRP CEC related publications, is summarized in Supplemental Figure 5.
The number of CEC associated papers published each year has increased linearly since 1998 
(Figure 1A). Furthermore, a PubMed search for the terms “consortia OR consortium” NOT 
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“bacteria OR microbe OR microbial” (to exclude papers on microbial consortia; searched on 
1/24/13) reveals an exponential increase in the number of papers containing these terms in 
their titles, abstracts, or authorship from 1985 to 2012 (Figure 1B). Further refining those 
search results by searching for the terms “cancer OR tumor” also reveal an exponential 
increase in cancer consortia papers since 1985. The rise of genome-wide association studies 
and the consequent need for extremely large numbers to reach adequate power has been 
cited as a major impetus for the formation of CEC (14, 15), however the trend towards team 
science in cancer research began well before publication of the first GWAS. Twenty-one 
(43%) of the CEC in the EGRP network were initiated before the first GWAS in the NHGRI 
GWAS Catalogue (16, 17).
CEC and Interdisciplinary Research
It has been proposed that team science, and therefore CEC-related science, should be ideally 
geared to support interdisciplinary research (18, 19). We define interdisciplinary research as 
“a mode of research by teams or individuals that integrates information, data, techniques, 
tools, perspectives, concepts, and/or theories from two or more disciplines or bodies of 
specialized knowledge to advance fundamental understanding or to solve problems whose 
solutions are beyond the scope of a single discipline or area of research practice” (20). To 
ascertain whether the publications produced by the 49 CEC examined are reflecting the CEC 
capability to support interdisciplinary research within an epidemiologic framework, the titles 
and abstracts for each of the 3,876 papers identified through the literature search described 
above were reviewed and each paper was assigned a primary scientific area. Papers were 
randomly assigned to 1 of 3 reviewers, with 10% of the papers assigned to all 3, and reviews 
were conducted over 14 rounds. Between each round, reviewers convened to discuss 
difficult to categorize papers, resolve discrepancies, and refine definitions. The scientific 
areas considered and their definitions are presented in Supplementary Table 1. A total of 
3,729 papers were assigned a primary scientific area. (See supplemental methods for 
exclusion criteria.) 56% of the papers being scored fell into the environmental, lifestyle, and 
genomic epidemiology categories. 11.9% of the papers involved development of new 
methods and technologies, 9.4% focused on clinical and translational research, and 11% 
were classified as biology which encompasses basic laboratory research, including studies in 
cell lines and animal models (Supplemental Figure 6). Considering the CEC consortia were 
primarily designed to address questions within the framework of population sciences, the 
diversity of the associate literature is striking and demonstrates the flexibility of 
interdisciplinary nature of the CECs.
The types of research projects being undertaken by CECs have extended their 
interdisciplinary scope, and evolved with the recent “genomic revolution” as shown by the 
trends in the CEC publication’s scientific areas over time (Figure 2). Classic epidemiology 
studies evaluating environmental and lifestyle exposures represent a large proportion of this 
literature and increase over time (1995–2011). However the number of CEC papers in 
genomics areas, including candidate genes (CG), gene characterization (GC), genome-wide 
association (GWA), linkage (LK), loss of heterozygosity (LOH), or next generation 
sequencing (NGS) has grown significantly since 2000 and since 2010 genomics papers 
represented the largest category of EGRP CEC-associated publications. The growth in 
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genomics publications is largely driven by the exponential growth of GWAS, which (as 
defined here) include initial scans as well as replication studies (Supplemental Figure 7). 
This trend mirrors the decline of linkage publications as the search for genetic determinants 
of cancer risk shifted from searching for rare, highly penetrant variations in family studies to 
the search for common variants with small effect sizes, primarily through association studies 
(Supplemental Figure 8). Publications pertaining to methods and technologies, biology, 
molecular epidemiology and clinical and translation areas show a more modest but steady 
increase.
Team Science and Translation
To evaluate the contribution of EGRP CECs to translational research 3,363 papers from the 
literature search were reviewed and coded by translational research phase. (See 
supplemental methods for exclusion criteria.) The phases of the translational research 
continuum have been previously described (21–24) and are summarized with example 
papers from our literature search in Table 3 (25–34). Coding for translational research phase 
was conducted concurrently with coding for primary scientific area following the same 
procedures. Overall, 2645 (79%) papers were coded as T0, 582 (17%) as T1, 112 (3.3%) as 
T2, 18 (0.5%) as T3, and only 6 (0.2%) as T4.
Previous analyses have observed that T2 and above studies account for a small fraction of 
NIH-funded cancer genetics research (24). It has been estimated that only 0.64% of cancer 
genetics papers published in 2007 would be scored T2 or above (23). In our database of 
CEC publications 136 (3.5%) were scored T2+ and when we limited CEC publications to 
cancer genetics papers published in 2007 we found 3.4% (6 out of 171) were scored T2 or 
above. The increased proportion of T2 or above papers among CEC associated cancer 
genetics papers was statistically significant (P-value 2.4×10−6; See supplemental methods 
for details of this analysis). This enrichment of papers further down the translational 
continuum indicates that the collaborative and interdisciplinary infrastructure of CEC may 
specifically facilitate translational research.
Challenges and Future Prospects
The extended CEC network examined does not include all consortia focusing on cancer 
research, but is highly representative of that segment of cancer research focusing on human 
populations to understand the causes of cancer and related outcomes. The CEC network is 
international in scope, allowing for the study of populations with diverse genetic background 
and lifestyles, and encompasses studies with a variety of designs, from familial to case-
control to prospective cohorts. The geographic distribution of the participating teams is still 
showing under-representation in low income regions, reflecting the need for infrastructure 
building in order to enrich the network to include populations with diverse genetic 
backgrounds, lifestyles and cultures. This may also reflect the fact that NIH funds primarily 
USA-based investigators and a more in-depth analysis of other sources of funding for 
international groups may reveal a more comprehensive panorama of international consortia. 
Tools of virtual communication (websites, portals) are widely used, but public dissemination 
of internal policies and processes and membership/participation criteria are still somewhat 
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limited in this Network. In this regard, complete transparency could greatly facilitate 
scientific exchange and rapid replication of initial results. Increasing the public posting of 
clear data sharing policies would facilitate not only collaborative projects among the 
investigators within the consortium, but also ready access to the consortia resources from 
new investigators interested in initiating collaborations thereby extending the consortia 
network. Consortia investigators are usually funded through a mosaic of mechanisms 
awarded by different funding agencies, and only rarely through special initiatives. For grants 
funded through NCI, adherence of the Principal Investigators to the NIH and NCI policies of 
data sharing is monitored through the lifetime of the grant and the application of current 
NIH/NCI policies on data sharing is mandatory and a condition for funding. For example, 
for some EGRP-funded consortia, applications for collaborative projects are tracked through 
a process of review and approval, and followed for productivity until completion (35, 36). It 
is to be noted that the data-sharing policies implemented by other national and international 
agencies vary considerable both in content and implementation (37). The NCI is in the 
process of establishing a database of consortia including the public posting of the internal 
and agency-mandated data sharing policies and to encourage maximum transparency. 
Increased transparency could greatly facilitate scientific exchange and rapid replication of 
initial results. A funding trend towards smaller CEC associated grants may indicate that 
while CEC require an initial substantial expenditure to establish the infrastructure necessary 
to conduct large-scale studies, their subsequently established resources and collaborative 
culture can be leveraged to support cost-efficient research effectively. Increased 
collaborations and synergism across consortia is also shown by the involvement of multiple 
CEC in individual grants. The increased success rate for consortia-related grant applications, 
as compared to the success rate for applications submitted to EGRP and NCI, may be 
symptomatic of the leverage provided by the extended consortia infrastructure and the 
extensive pre-application scrutiny and constructive pre-review usually provided by the 
consortia teams.
Our ascertainment of CEC-related publications has some limitations. Publications listed on a 
consortium’s website are likely to be truly consortia-associated. However, 9 of the consortia 
did not have public websites, and of the remaining 40 websites, only 31 (62%) displayed a 
publication list. The completeness and update frequencies of the website publication lists 
were also variable. Publications captured by querying PubMed for the CEC name or 
abbreviation (followed by confirmation through independent review) are, almost by 
definition, CEC-related. However, CEC publication policies vary considerably and it is not 
uncommon for contributing CEC to only be mentioned in the methods, acknowledgments, or 
supplementary materials of a paper, i.e. sections that are not queried in PubMed searches, 
leading to under-ascertainment. Examination of the manuscripts associated with a sample of 
four established large-scale consortia funded by NIH (two of which were not included in the 
analyses presented in this manuscript as they did not respond to the selection criteria used) 
shows that acknowledgment of publications in consortia-related manuscripts, cited by their 
websites or listed in the associated grants, varied considerably across consortia, from 100% 
to 52%, (see Supplemental Table 2). This may be due to journal policies on 
acknowledgment format, to the lack of standard acknowledgement language distributed to 
the collaborators or to the absence of appropriate consortium acknowledgment requirements. 
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CEC-associated grants often encompass multiple specific aims, which may or may not 
require CEC resources. Therefore, when searching by acknowledged CEC-associated grant 
numbers we may be over-ascertaining CEC papers; this is in contrast to the website review 
and name/abbreviation searches which usually under-ascertain CEC related publications. 
Another possible source of measurement error is that CEC are typically supported through a 
mosaic of funding mechanisms, including grants from funding sources other than EGRP. 
Our grant number searches were limited to manuscripts citing EGRP-funded grants. While 
each individual search has limitations, we combined several strategies, with different 
strengths and weaknesses, to obtain an overall picture of the scientific productivity of this 
network of CECs. Results not only show a consistent increase in scientific output, after an 
initial lag period for the establishment of the needed infrastructures, but also the capability 
of consortia to support interdisciplinary science beyond the domains of classic 
epidemiology. The enrichment in the production of publications further down the 
translational continuum (T2 and higher) may also indicate the potential for unique 
contributions of CEC to translational research as a result of their interdisciplinary, team 
science approach. Interdisciplinary science is the first step in the path to translation and large 
consortia network may in the future provide an accelerated avenue to the development of 
preventive intervention and new therapeutic strategies.
We have described an extensive collection of cancer consortia which is showing the initial 
characteristics of an emerging interactive network as also shown by extensive co-authorship 
and co-membership across consortia (Abstract under review). Public posting of internal 
policies and processes, especially for what concerns data sharing and publications, and 
public availability of descriptive data on existing CECs resources (populations 
characteristics, protocols, questionnaires, publications, etc.), could considerably expedite 
collaborations across the consortia and with the scientific community at large. The combined 
expertise and infrastructure represented within this established network could also be of use 
in developing training approaches for young investigators across the spectrum of cancer 
epidemiology and related disciplines. This emerging Network of Cancer Consortia (NOCC) 
has demonstrated the capability to incorporate novel genomics technologies (genome-wide 
genotyping and next-generation sequencing technologies), and has the potential to be a 
fertile ground for the high-throughput application of different ‘omics’ approaches (38). 
Publication output shows that multi-level data sets are being assembled, integrated and 
analyzed to address hypotheses of increasing complexity.
It has been proposed that 21st century epidemiology will be driven by four overlapping 
drivers in the production of new knowledge and its translation: acceleration of trends toward 
multiple group interactive networks; rapid incorporation of emerging technologies into 
large-scale population studies; the building of infrastructure through which to assess factors 
and interventions at multiple levels and the capability of effectively integrating multi-level 
data sets for increasingly complex analyses (39). The extensive population resource, the 
reliance on interdisciplinary teams, and the facilitation of the translational pipeline by this 
emerging network of consortia may offer a supportive infrastructure to begin implementing 
these transformative goals.
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References
1. Wuchty S, Jones BF, Uzzi B. The increasing dominance of teams in production of knowledge. 
Science. 2007; 316(5827):1036–9. Epub 2007/04/14. [PubMed: 17431139] 
2. Caporaso NE, Bennett SN. The Rise of Consortia. Nature Precedings [Internet]. 2011
3. Boffetta P, Colditz GA, Potter JD, Kolonel L, Robson PJ, Malekzadeh R, et al. Cohorts and 
consortia conference: a summary report (Banff, Canada, June 17–19, 2009). Cancer causes & 
control: CCC. 2011; 22(3):463–8. Epub 2011/01/05. [PubMed: 21203821] 
4. Vegvari A, Welinder C, Lindberg H, Fehniger TE, Marko-Varga G. Biobank resources for future 
patient care: developments, principles and concepts. Journal of clinical bioinformatics. 2011; 1(1):
24. Epub 2011/09/20. [PubMed: 21923917] 
5. Hoover RN. The evolution of epidemiologic research: from cottage industry to “big” science. 
Epidemiology. 2007; 18(1):13–7. Epub 2006/12/21. [PubMed: 17179754] 
6. EGRP-Supported Cancer Epidemiology Consortia. Bethesda, MD: National Insititutes of 
Health(US); Available from: http://epi.grants.cancer.gov/Consortia/
7. Breast Cancer And The Environment Research Centers. Bethesda, MD: National Institutes of Health 
(US); 2002. Available from: http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-03-001.html
8. Cooperative Family Registry for Epidemiologic Studies of Breast Cancer. Bethesda, MD: National 
Institutes of Health (US); 1994. Available from: http://grants.nih.gov/grants/guide/rfa-files/RFA-
CA-95-003.html
9. Cooperative Family Registry for Epidemiologic Studies of Colon Cancer. Bethesda, MD: National 
Institutes of Health (US); 1996. Available from: http://grants.nih.gov/grants/guide/notice-files/
not96-192.html
10. NIH Sharing Policies and Related Guidance on NIH-Funded Research Resources. Bethesda, MD: 
National Institutes of Health (US); Available from: http://grants.nih.gov/grants/sharing.htm
11. NIH RePORTER: Research Project Success Rates by Type and Activity. Bethesda, MD: National 
Insititutes of Health(US); Available from: http://report.nih.gov/success_rates/
Success_ByActivity.cfm
12. Hall KL, Feng AX, Moser RP, Stokols D, Taylor BK. Moving the science of team science forward: 
collaboration and creativity. American journal of preventive medicine. 2008; 35(2 Suppl):S243–9. 
Epub 2008/08/23. [PubMed: 18619406] 
13. PubMed. Bethesda, MD: U.S. National Library of Medicine; Available from: http://
www.ncbi.nlm.nih.gov/pubmed
14. Austin MA, Hair MS, Fullerton SM. Research Guidelines in the Era of Large-scale Collaborations: 
An Analysis of Genome-wide Association Study Consortia. American journal of epidemiology. 
2012; 175(9):962–9. Epub 2012/04/12. [PubMed: 22491085] 
15. Thun MJ, Hoover RN, Hunter DJ. Bigger, better, sooner--scaling up for success. Cancer 
epidemiology, biomarkers & prevention: a publication of the American Association for Cancer 
Research, cosponsored by the American Society of Preventive . Oncology. 2012; 21(4):571–5. 
Epub 2012/03/01. 
16. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential 
etiologic and functional implications of genome-wide association loci for human diseases and 
traits. Proceedings of the National Academy of Sciences of the United States of America. 2009; 
106(23):9362–7. Epub 2009/05/29. [PubMed: 19474294] 
17. A Catalog of Published Genome-Wide Association Studies. [database on the Internet]. Available 
from: www.genome.gov/gwastudies
18. Disis ML, Slattery JT. The road we must take: multidisciplinary team science. Science translational 
medicine. 2010; 2(22):22cm9. Epub 2010/04/09. 
Burgio et al. Page 9
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2015 December 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
19. Rebbeck TR, Paskett E, Sellers TA. Fostering transdisciplinary science. Cancer epidemiology, 
biomarkers & prevention: a publication of the American Association for Cancer Research, 
cosponsored by the American Society of Preventive . Oncology. 2010; 19(5):1149–50. Epub 
2010/05/08. 
20. Facilitating Interdisciplinary Research. The National Academies Press; 2004. 
21. Khoury MJ, Coates RJ, Evans JP. Evidence-based classification of recommendations on use of 
genomic tests in clinical practice: dealing with insufficient evidence. Genetics in medicine: official 
journal of the American College of Medical Genetics. 2010; 12(11):680–3. Epub 2010/10/27. 
[PubMed: 20975567] 
22. Khoury MJ, Gwinn M, Yoon PW. The continuum of translation research in genomic medicine: 
how can we accelerate the appropriate integration of human genome discoveries into health care 
and disease prevention. Genetics in medicine: official journal of the American College of Medical 
Genetics. 2007; 9:665–74. [PubMed: 18073579] 
23. Schully SD, Benedicto CB, Gillanders EM, Wang SS, Khoury MJ. Translational research in cancer 
genetics: the road less traveled. Public health genomics. 2011; 14:1–8. [PubMed: 20051673] 
24. Schully SD, Benedicto CB, Khoury MJ. How can we stimulate translational research in cancer 
genomics beyond bench to bedside? Genetics in medicine: official journal of the American 
College of Medical Genetics. 2012; 14(1):169–70. Epub 2012/01/13. [PubMed: 22237448] 
25. Freedman ND, Murray LJ, Kamangar F, Abnet CC, Cook MB, Nyren O, et al. Alcohol intake and 
risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut. 
2011; 60(8):1029–37. Epub 2011/03/17. [PubMed: 21406386] 
26. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, et al. Association of a 
microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic 
leukemia. JAMA: the journal of the American Medical Association. 2011; 305(1):59–67. Epub 
2011/01/06. 
27. Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, et al. Modification 
of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. 
Cancer research. 2001; 61(14):5420–4. Epub 2001/07/17. [PubMed: 11454686] 
28. Kastrinos F, Steyerberg EW, Mercado R, Balmana J, Holter S, Gallinger S, et al. The 
PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on 
cancer history. Gastroenterology. 2011; 140(1):73–81. Epub 2010/08/24. [PubMed: 20727894] 
29. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-
reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA: 
the journal of the American Medical Association. 2010; 304(9):967–75. Epub 2010/09/03. 
30. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for 
individuals perceived to be genetically predisposed to melanoma: A consensus statement of the 
Melanoma Genetics Consortium. Journal of clinical oncology: official journal of the American 
Society of Clinical Oncology. 1999; 17(10):3245–51. Epub 1999/10/03. [PubMed: 10506626] 
31. Wirtzfeld DA, Mikula L, Gryfe R, Ravani P, Dicks EL, Parfrey P, et al. Concordance with clinical 
practice guidelines for adjuvant chemotherapy in patients with stage I–III colon cancer: experience 
in 2 Canadian provinces. Canadian journal of surgery Journal canadien de chirurgie. 2009; 52(2):
92–7. Epub 2009/04/29. [PubMed: 19399202] 
32. Watkins KE, Way CY, Fiander JJ, Meadus RJ, Esplen MJ, Green JS, et al. Lynch syndrome: 
barriers to and facilitators of screening and disease management. Hereditary cancer in clinical 
practice. 2011; 9:8. Epub 2011/09/09. [PubMed: 21899746] 
33. Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of 
microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal 
cancer. Annals of internal medicine. 2001; 135(8 Pt 1):577–88. Epub 2001/10/17. [PubMed: 
11601929] 
34. Newcomb PA, Storer BE, Morimoto LM, Templeton A, Potter JD. Long-term efficacy of 
sigmoidoscopy in the reduction of colorectal cancer incidence. Journal of the National Cancer 
Institute. 2003; 95(8):622–5. Epub 2003/04/17. [PubMed: 12697855] 
35. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, et al. The Breast Cancer 
Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational 
Burgio et al. Page 10
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2015 December 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
studies of the genetic epidemiology of breast cancer. Breast cancer research: BCR. 2004; 
6(4):R375–89. Epub 2004/06/26. [PubMed: 15217505] 
36. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, et al. Colon Cancer Family 
Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer 
epidemiology, biomarkers & prevention: a publication of the American Association for Cancer 
Research, cosponsored by the American Society of Preventive. Oncology. 2007; 16(11):2331–43. 
Epub 2007/11/06. 
37. Knoppers BM, Harris JR, Tasse AM, Budin-Ljosne I, Kaye J, Deschenes M, et al. Towards a data 
sharing Code of Conduct for international genomic research. Genome medicine. 2011; 3(7):46. 
Epub 2011/07/27. [PubMed: 21787442] 
38. Verma M, Khoury MJ, Ioannidis JP. Opportunities and challenges for selected emerging 
technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase 
profiling. Cancer epidemiology, biomarkers & prevention: a publication of the American 
Association for Cancer Research, cosponsored by the American Society of Preventive . Oncology. 
2013; 22(2):189–200. Epub 2012/12/18. 
39. Lam TK, Spitz M, Schully SD, Khoury MJ. “Drivers” of Translational Cancer Epidemiology in the 
21st Century: Needs and Opportunities. Cancer epidemiology, biomarkers & prevention: a 
publication of the American Association for Cancer Research, cosponsored by the American 
Society of Preventive Oncology. 2013 Epub 2013/01/17. 
40. Onar A, Ramamurthy U, Wallace D, Boyett JM. An operational perspective of challenging 
statistical dogma while establishing a modern, secure distributed data management and imaging 
transport system: the Pediatric Brain Tumor Consortium phase I experience. Clinical and 
translational science. 2009; 2(2):143–9. Epub 2010/05/07. [PubMed: 20443880] 
41. Poussaint TY, Phillips PC, Vajapeyam S, Fahey FH, Robertson RL, Osganian S, et al. The 
Neuroimaging Center of the Pediatric Brain Tumor Consortium-collaborative neuroimaging in 
pediatric brain tumor research: a work in progress. AJNR American journal of neuroradiology. 
2007; 28(4):603–7. Epub 2007/04/10. [PubMed: 17416804] 
42. Cai Q, Long J, Lu W, Qu S, Wen W, Kang D, et al. Genome-wide association study identifies 
breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Human 
molecular genetics. 2011; 20(24):4991–9. Epub 2011/09/13. [PubMed: 21908515] 
43. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE. An international 
initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the 
Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast cancer 
research: BCR. 2007; 9(2):104. Epub 2007/05/01. [PubMed: 17466083] 
44. Neuhausen SL, Ozcelik H, Southey MC, John EM, Godwin AK, Chung W, et al. BRCA1 and 
BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative 
research. Breast cancer research and treatment. 2009; 116(2):379–86. Epub 2008/08/16. [PubMed: 
18704680] 
45. Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, et al. 
ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an 
international initiative to evaluate risk and clinical significance associated with sequence variation 
in BRCA1 and BRCA2 genes. Human mutation. 2012; 33(1):2–7. Epub 2011/10/13. [PubMed: 
21990146] 
46. Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, Chanock SJ, et al. A candidate gene 
approach to searching for low-penetrance breast and prostate cancer genes. Nature reviews Cancer. 
2005; 5(12):977–85. Epub 2005/12/13. 
47. Jia WH, Zhang B, Matsuo K, Shin A, Xiang YB, Jee SH, et al. Genome-wide association analyses 
in East Asians identify new susceptibility loci for colorectal cancer. Nature genetics. 2013; 45(2):
191–6. Epub 2012/12/25. [PubMed: 23263487] 
48. Olson SH, Chen C, De Vivo I, Doherty JA, Hartmuller V, Horn-Ross PL, et al. Maximizing 
resources to study an uncommon cancer: E2C2--Epidemiology of Endometrial Cancer 
Consortium. Cancer causes & control: CCC. 2009; 20(4):491–6. Epub 2009/01/10. [PubMed: 
19132539] 
49. Conway DI, Hashibe M, Boffetta P, Wunsch-Filho V, Muscat J, La Vecchia C, et al. Enhancing 
epidemiologic research on head and neck cancer: INHANCE - The international head and neck 
Burgio et al. Page 11
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2015 December 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
cancer epidemiology consortium. Oral oncology. 2009; 45(9):743–6. Epub 2009/05/16. [PubMed: 
19442571] 
50. Boffetta P, Armstrong B, Linet M, Kasten C, Cozen W, Hartge P. Consortia in cancer 
epidemiology: lessons from InterLymph. Cancer epidemiology, biomarkers & prevention: a 
publication of the American Association for Cancer Research, cosponsored by the American 
Society of Preventive. Oncology. 2007; 16(2):197–9. Epub 2007/02/16. 
51. Kricker A, Armstrong BK, Goumas C, Kanetsky P, Gallagher RP, Begg CB, et al. MC1R genotype 
may modify the effect of sun exposure on melanoma risk in the GEM study. Cancer causes & 
control: CCC. 2010; 21(12):2137–47. Epub 2010/08/20. [PubMed: 20721616] 
52. Ragin CC, Taioli E, McFarlane-Anderson N, Avery G, Bennett F, Bovell-Benjamin A, et al. 
African-Caribbean cancer consortium for the study of viral, genetic and environmental cancer risk 
factors. Infectious agents and cancer. 2007; 2:17. Epub 2007/09/26. [PubMed: 17892589] 
53. Rolland B, Smith BR, Potter JD. Coordinating centers in cancer epidemiology research: the Asia 
Cohort Consortium coordinating center. Cancer epidemiology, biomarkers & prevention: a 
publication of the American Association for Cancer Research, cosponsored by the American 
Society of Preventive. Oncology. 2011; 20(10):2115–9. Epub 2011/08/02. 
54. Song M, Rolland B, Potter JD, Kang D. Asia Cohort Consortium: challenges for collaborative 
research. Journal of epidemiology/Japan Epidemiological Association. 2012; 22(4):287–90. Epub 
2012/06/08. [PubMed: 22672913] 
55. Anton-Culver H, Ziogas A, Bowen D, Finkelstein D, Griffin C, Hanson J, et al. The Cancer 
Genetics Network: recruitment results and pilot studies. Community genetics. 2003; 6(3):171–7. 
Epub 2004/07/09. [PubMed: 15237201] 
56. Brown RC, Dwyer T, Kasten C, Krotoski D, Li Z, Linet MS, et al. Cohort profile: the International 
Childhood Cancer Cohort Consortium (I4C). International journal of epidemiology. 2007; 36(4):
724–30. Epub 2007/01/27. [PubMed: 17255350] 
57. West C, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, et al. Establishment of a 
Radiogenomics Consortium. International journal of radiation oncology, biology, physics. 2010; 
76(5):1295–6. Epub 2010/03/27. 
58. Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, et al. Obesity and risk of 
ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-
related cancer. 2013; 20(2):251–62. Epub 2013/02/14. [PubMed: 23404857] 
59. Petersen GM, de Andrade M, Goggins M, Hruban RH, Bondy M, Korczak JF, et al. Pancreatic 
cancer genetic epidemiology consortium. Cancer epidemiology, biomarkers & prevention: a 
publication of the American Association for Cancer Research, cosponsored by the American 
Society of Preventive. Oncology. 2006; 15(4):704–10. Epub 2006/04/15. 
60. Doherty R, Lubinski J, Manguoglu E, Luleci G, Christie M, Craven P, et al. AIDIT and IMPACT: 
building research collaborations in targeted prostate cancer screening. Journal of BUON: official 
journal of the Balkan Union of Oncology. 2006; 11(4):415–8. Epub 2007/02/20. 
61. Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, et al. Targeted prostate 
cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: 
preliminary analysis of the results of the IMPACT study. BJU international. 2011; 107(1):28–39. 
Epub 2010/09/16. [PubMed: 20840664] 
62. Mitra AV, Bancroft EK, Eeles RA. A review of targeted screening for prostate cancer: introducing 
the IMPACT study. BJU international. 2007; 99(6):1350–5. Epub 2007/04/11. [PubMed: 
17419707] 
63. Schaid DJ, Chang BL. Description of the International Consortium For Prostate Cancer Genetics, 
and failure to replicate linkage of hereditary prostate cancer to 20q13. The Prostate. 2005; 63(3):
276–90. Epub 2004/12/16. [PubMed: 15599943] 
64. Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, et al. HOXB13 is a susceptibility gene 
for prostate cancer: results from the International Consortium for Prostate Cancer Genetics 
(ICPCG). Human genetics. 2013; 132(1):5–14. Epub 2012/10/16. [PubMed: 23064873] 
65. Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, et al. Global patterns of 
prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate cancer. 
2013; 2013:560857. Epub 2013/03/12. [PubMed: 23476788] 
Burgio et al. Page 12
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2015 December 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
66. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, et al. Seven prostate 
cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature 
genetics. 2011; 43(8):785–91. Epub 2011/07/12. [PubMed: 21743467] 
Burgio et al. Page 13
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2015 December 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
(A) The number of EGRP CEC associated papers by year, from 1996 – 2011. The linear 
trend line excludes data points from 1996 and 1997. (B) The number of papers retrieved, by 
year, from PubMed queries using the terms “consortia” or “consortium” on cancer and on all 
topics from 1985 to 2012.
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Figure 2. 
The number of papers in scientific areas by year; definitions of each scientific area are in 
Supplementary Table 1. Genomics=Candidate Gene, Gene Characterization, Genome-wide 
Association, Gene-Environment, Linkage, Loss of Heterozygocity, and Next-generation 
Sequencing papers combined; EL=Environment, Lifestyle & Descriptive Epidemiology; 
MT=Methods and Technologies; BIO=Biology; CT=Clinical & Translational; 
ME=Molecular Epidemiology; RS=Resources; BR=Behavioral.
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